APD371, a peripherally restricted, highly selective, full agonist of the Cannabinoid Receptor 2 (CB2), reduces colitis-induced visceral hypersensitivity in rats

被引：0
|
作者：
Brierley, S. [1 ]
Castro, J. [1 ]
Maddern, J. [1 ]
Garcia-Caraballo, S. [1 ]
Lindstrom, B. [2 ]
Adams, J. [2 ]
机构：
[1] Flinders Univ S Australia, Adelaide, SA, Australia
[2] Arena Pharmaceut Inc, San Diego, CA USA
来源：
NEUROGASTROENTEROLOGY AND MOTILITY | 2018年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
042
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl) methanone (SAB378), a Peripherally Restricted Cannabinoid CB1/CB2 Receptor Agonist, Inhibits Gastrointestinal Motility but Has No Effect on Experimental Colitis in Mice
    Cluny, Nina L.
    Keenan, Catherine M.
    Duncan, Marnie
    Fox, Alyson
    Lutz, Beat
    Sharkey, Keith A.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2010, 334 (03): : 973 - 980
  • [42] Anti-Proliferative Properties and Proapoptotic Function of New CB2 Selective Cannabinoid Receptor Agonist in Jurkat Leukemia Cells
    Capozzi, Antonella
    Mattei, Vincenzo
    Martellucci, Stefano
    Manganelli, Valeria
    Saccomanni, Giuseppe
    Garofalo, Tina
    Sorice, Maurizio
    Manera, Clementina
    Misasi, Roberta
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (07)
  • [43] Cannabinoid receptor-2 (CB2) agonist ameliorates colitis in IL-10-/- mice by attenuating the activation of T cells and promoting their apoptosis
    Singh, Udai P.
    Singh, Narendra P.
    Singh, Balwan
    Price, Robert L.
    Nagarkatti, Mitzi
    Nagarkatti, Prakash S.
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2012, 258 (02) : 256 - 267
  • [44] SAFETY AND EFFICACY OF OLORINAB, A PERIPHERALLY RESTRICTED, HIGHLY SELECTIVE, CANNABINOID RECEPTOR 2 AGONIST IN A PHASE 2A STUDY IN CHRONIC ABDOMINAL PAIN ASSOCIATED WITH CROHN'S DISEASE
    Yacyshyn, Bruce
    Ginsberg, Daniel C.
    Gilder, Kye
    Walsh, Brandon
    English, Brett
    Turner, Stewart A.
    Klassen, Preston
    Hanauer, Stephen B.
    Barish, Charles F.
    Higgins, Peter D.
    GASTROENTEROLOGY, 2019, 156 (06) : S665 - S665
  • [45] CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: Potential role for CB2-selective ligands as immunosuppressive agents
    Lombard, Catherine
    Nagarkatti, Mitzi
    Nagarkatti, Prakash
    CLINICAL IMMUNOLOGY, 2007, 122 (03) : 259 - 270
  • [46] Cannabinoid CB2 receptor antagonist prevents cannabidiol-induced decrease in body weight gains in rats
    Ignatowska-Jankowska, B.
    Jankowski, M. M.
    Glac, W.
    Swiergiel, A. B.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S600 - S600
  • [47] A Cannabinoid CB2 receptor agonist attenuates experimental autoimmune encephalomyelitis (EAE) and reduces MOG-specific T cell proliferation
    Zhang, Ming
    Yen, Jui-Hung
    Kharullina, Tanzilya
    Ganea, Doina
    Tuma, Ronald F.
    FASEB JOURNAL, 2007, 21 (06): : A1393 - A1393
  • [48] Evaluation of selective cannabinoid CB1 and CB2 receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis
    Tambaro, Simone
    Casu, Maria Antonietta
    Mastinu, Andrea
    Lazzari, Paolo
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2014, 729 : 67 - 74
  • [49] Potent immunomodulatory activity of a highly selective cannabinoid CB2 agonist on immune cells from healthy subjects and patients with multiple sclerosis
    Annunziata, Pasquale
    Cioni, Chiara
    Mugnaini, Claudia
    Corelli, Federico
    JOURNAL OF NEUROIMMUNOLOGY, 2017, 303 : 66 - 74
  • [50] Selective Activation of Cannabinoid CB2 Receptors Suppresses Neuropathic Nociception Induced by Treatment with the Chemotherapeutic Agent Paclitaxel in Rats
    Rahn, Elizabeth J.
    Zvonok, Alexander M.
    Thakur, Ganesh A.
    Khanolkar, Atmaram D.
    Makriyannis, Alexandros
    Hohmann, Andrea G.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 327 (02): : 584 - 591
12345